Monaco Asset Management SAM Has $727,000 Stock Holdings in Nektar Therapeutics (NASDAQ:NKTR)

Monaco Asset Management SAM lessened its holdings in shares of Nektar Therapeutics (NASDAQ:NKTR - Free Report) by 47.4% in the first quarter, according to its most recent filing with the SEC. The firm owned 1,068,899 shares of the biopharmaceutical company's stock after selling 963,969 shares during the period. Monaco Asset Management SAM owned 0.57% of Nektar Therapeutics worth $727,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of NKTR. Sei Investments Co. boosted its stake in Nektar Therapeutics by 50.6% in the 4th quarter. Sei Investments Co. now owns 94,152 shares of the biopharmaceutical company's stock worth $88,000 after purchasing an additional 31,654 shares during the period. JPMorgan Chase & Co. boosted its stake in Nektar Therapeutics by 29.5% in the 4th quarter. JPMorgan Chase & Co. now owns 1,182,995 shares of the biopharmaceutical company's stock worth $1,100,000 after purchasing an additional 269,695 shares during the period. Wellington Management Group LLP boosted its stake in Nektar Therapeutics by 10.4% in the 4th quarter. Wellington Management Group LLP now owns 522,409 shares of the biopharmaceutical company's stock worth $486,000 after purchasing an additional 49,319 shares during the period. Wells Fargo & Company MN boosted its stake in Nektar Therapeutics by 26.5% in the 4th quarter. Wells Fargo & Company MN now owns 108,975 shares of the biopharmaceutical company's stock worth $101,000 after purchasing an additional 22,822 shares during the period. Finally, Renaissance Technologies LLC boosted its stake in shares of Nektar Therapeutics by 17.5% during the 4th quarter. Renaissance Technologies LLC now owns 3,910,786 shares of the biopharmaceutical company's stock worth $3,637,000 after buying an additional 583,153 shares during the last quarter. Institutional investors and hedge funds own 75.88% of the company's stock.

Nektar Therapeutics Stock Up 5.9%

Shares of NKTR traded up $1.28 during mid-day trading on Friday, hitting $22.96. 504,568 shares of the company's stock were exchanged, compared to its average volume of 911,784. Nektar Therapeutics has a 52 week low of $6.45 and a 52 week high of $37.38. The stock's 50-day simple moving average is $18.44 and its 200-day simple moving average is $13.83. The firm has a market cap of $284.93 million, a price-to-earnings ratio of -2.39 and a beta of 0.95.

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) last announced its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($3.30) EPS for the quarter, missing the consensus estimate of ($2.70) by ($0.60). Nektar Therapeutics had a negative return on equity of 329.54% and a negative net margin of 152.49%. The business had revenue of $10.46 million for the quarter, compared to the consensus estimate of $15.61 million. During the same period in the prior year, the business posted ($2.70) earnings per share. Analysts forecast that Nektar Therapeutics will post -0.72 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

NKTR has been the subject of a number of recent research reports. William Blair restated a "market perform" rating on shares of Nektar Therapeutics in a research note on Monday, May 12th. HC Wainwright increased their price objective on shares of Nektar Therapeutics to $120.00 and gave the stock a "buy" rating in a research note on Tuesday, June 24th. Wall Street Zen downgraded shares of Nektar Therapeutics from a "hold" rating to a "sell" rating in a research note on Wednesday, May 14th. B. Riley increased their price objective on shares of Nektar Therapeutics from $60.00 to $85.00 and gave the stock a "buy" rating in a research note on Tuesday, July 8th. Finally, BTIG Research upped their target price on shares of Nektar Therapeutics from $60.00 to $100.00 and gave the company a "buy" rating in a report on Tuesday, June 24th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $88.33.

Nektar Therapeutics Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.